Lakefront Biotherapeutics (LKFT) Tax Provisions (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Tax Provisions for 11 consecutive years, with -$81952.2 the latest figure, recorded in Q1 2026.

• In Q1 2026, Tax Provisions fell 104.29% year-over-year to -$81952.2; the TTM figure through Mar 2026 stood at -$23.7 million (down 871.9% YoY), while the FY2025 annual figure was -$21.7 million, down 1025.03% from the prior year.
• Tax Provisions advanced to -$81952.2 in Q1 2026 per LKFT's latest filing, from -$44.1 million in the prior quarter.
• Across five years, Tax Provisions topped out at $23.2 million in Q3 2025 and bottomed at -$44.1 million in Q4 2025.
• Historically, Tax Provisions has averaged -$2.1 million across 5 years, with a median of -$106859.5 in 2024.
• On a YoY basis, Tax Provisions climbed as much as 1066.89% in 2025 and fell as far as 41193.98% in 2025.
• Lakefront Biotherapeutics' Tax Provisions stood at $3.9 million in 2022, then plunged by 158.26% to -$2.3 million in 2023, then surged by 95.27% to -$106859.5 in 2024, then plunged by 41193.98% to -$44.1 million in 2025, then soared by 99.81% to -$81952.2 in 2026.
• Business Quant data shows LKFT's Tax Provisions at -$81952.2 in Q1 2026, -$44.1 million in Q4 2025, and $23.2 million in Q3 2025.